GlassScriptPhysician profile
Vikas K Pilly
NPI 1841302403
$19,136.36
in general payments reported to CMS, 2019-2025
25 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $15K · 2021: $547 · 2022: $795 · 2023: $1,143 · 2024: $921 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Travel and Lodging: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.75 |
| Travel and Lodging | $215.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caerus Corp. | $14,875.00 | 2020 | |
| Boston Scientific Corporation | $1,233.35 | 2021-2025 | Wavewriter Alpha Prime 16, Varithena Administration Pack |
| Abbott Laboratories | $735.71 | 2019-2025 | Axium, Proclaim, Octrode |
| Averitas Pharma INC. | $574.39 | 2023-2025 | Qutenza |
| Nevro Corp. | $370.95 | 2019-2023 | Senza |
| Curonix LLC | $364.81 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $361.30 | 2019-2025 | Ztlido |
| International Rehabilitative Sciences, INC | $179.77 | 2021-2022 | |
| Uswm, LLC | $76.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $54.69 | 2022-2024 | Belbuca |
| Vertex Pharmaceuticals Incorporated | $47.37 | 2024-2025 | |
| Pfizer INC. | $35.64 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.77 | 2021 | |
| Abbvie INC. | $25.90 | 2021 | |
| Biodelivery Sciences International, INC. | $25.75 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.99 | 2024 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $17.32 | 2024 | Evoke |
| Acadia Pharmaceuticals INC | $17.12 | 2019 | |
| Sentynl Therapeutics, INC. | $16.57 | 2019 | |
| Zyla Life Sciences, INC. | $14.70 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.45 | 2019 | |
| Lilly USA, LLC | $12.03 | 2019 | |
| Shionogi INC | $11.93 | 2019 | |
| Ucb, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Pilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.